University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Estimating the returns to United Kingdom publicly funded musculoskeletal disease research in terms of net value of improved health outcomes

Glover, Matthew, Montague, Erin, Pollitt, Alexandra, Guthrie, Susan, Hanney, Stephen, Buxton, Martin and Grant, Jonathan (2018) Estimating the returns to United Kingdom publicly funded musculoskeletal disease research in terms of net value of improved health outcomes Health Research Policy and Systems, 16, 1.

Full text not available from this repository.

Abstract

Background

Building on an approach applied to cardiovascular and cancer research, we estimated the economic returns from United Kingdom public- and charitable-funded musculoskeletal disease (MSD) research that arise from the net value of the improved health outcomes in the United Kingdom.

Methods

To calculate the economic returns from MSD-related research in the United Kingdom, we estimated (1) the public and charitable expenditure on MSD-related research in the United Kingdom between 1970 and 2013; (2) the net monetary benefit (NMB), derived from the health benefit in quality adjusted life years (QALYs) valued in monetary terms (using a base-case value of a QALY of £25,000) minus the cost of delivering that benefit, for a prioritised list of interventions from 1994 to 2013; (3) the proportion of NMB attributable to United Kingdom research; and (4) the elapsed time between research funding and health gain. The data collected from these four key elements were used to estimate the internal rate of return (IRR) from MSD-related research investments on health benefits. We analysed the uncertainties in the IRR estimate using a one-way sensitivity analysis.

Results

Expressed in 2013 prices, total expenditure on MSD-related research from 1970 to 2013 was £3.5 billion, and for the period used to estimate the rate of return, 1978-1997, was £1.4 billion. Over the period 1994–2013 the key interventions analysed produced 871,000 QALYs with a NMB of £16 billion, allowing for the net NHS costs resulting from them and valuing a QALY at £25,000. The proportion of benefit attributable to United Kingdom research was 30% and the elapsed time between funding and impact of MSD treatments was 16 years. Our best estimate of the IRR from MSD-related research was 7%, which is similar to the 9% for CVD and 10% for cancer research.

Conclusions

Our estimate of the IRR from the net health gain to public and charitable funding of MSD-related research in the United Kingdom is substantial, and justifies the research investments made between 1978 and 1997. We also demonstrated the applicability of the approach previously used in assessing the returns from cardiovascular and cancer research. Inevitably, with a study of this kind, there are a number of important assumptions and caveats that we highlight, and these can inform future research.

Item Type: Article
Divisions : Faculty of Health and Medical Sciences > School of Biosciences and Medicine
Authors :
NameEmailORCID
Glover, Matthewmatthew.glover@surrey.ac.uk
Montague, Erin
Pollitt, Alexandra
Guthrie, Susan
Hanney, Stephen
Buxton, Martin
Grant, Jonathan
Date : 10 January 2018
Funders : Wellcome Trust, Arthritis Research UK, Medical Research Council (MRC), National Institute for Health Research (NIHR), Academy of Medical Sciences
DOI : 10.1186/s12961-017-0276-7
OA Location : https://health-policy-systems.biomedcentral.com/track/pdf/10.1186/s12961-017-0276-7
Copyright Disclaimer : Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Uncontrolled Keywords : Medical research investment; QALYs; Musculoskeletal disease; Medical research charities; Value of health; Rate of return; Elapsed time; Research payback
Depositing User : Clive Harris
Date Deposited : 29 Apr 2020 14:19
Last Modified : 29 Apr 2020 14:19
URI: http://epubs.surrey.ac.uk/id/eprint/855405

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800